[1]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18-21.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(04):18-21.[doi:10.3969/j.issn.1671-7414.2019.04.005]
点击复制

肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年04期
页码:
18-21
栏目:
论著
出版日期:
2019-08-20

文章信息/Info

Title:
Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma
文章编号:
1671-7414(2019)04-018-04
作者:
吴良银a; 李文丽b; 刘 俊a
(粤北人民医院a.检验科; b.生殖医学中心,广东韶关 512025)
Author(s):
WU Liang-yina; LI Wen-lib; LIU Juna
(a.Department of Clinical Laboratory; b.Reproductive Center,Northern Guangdong People's Hospital,Guangdong Shaoguan 512025,China)
关键词:
肝细胞癌;  长链非编码RNA(LncRNA);  靶基因;  生物信息学
分类号:
R735.7; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.04.005
文献标志码:
A
摘要:
目的 通过癌症基因图谱(the cancer genome atlas,TCGA)数据库,利用生物信息学方法构建与肝细胞癌患者生存预后相关的长链非编码RNA(LncRNA)筛选模型,建立肝细胞癌诊断和预后相关的LncRNA,为研究肝细胞癌的发生发展及预后提供新的研究思路,有望成为新的治疗靶点。方法 从癌症基因图谱(TCGA)数据库中下载424例肝细胞癌患者的RNA表达谱数据和相应的临床资料,其中包括374例肿瘤组织和50例正常对照。通过R语言的edgeR包,获取在正常组织和肝细胞癌组织中差异表达的LncRNA,并使用单因素Cox回归分析筛选出与预后相关的LncRNA。用lasso回归和多因素回归分析建立与肝细胞癌预后相关LncRNA模型,绘制受试者工作特征曲线,验证其模型的可靠性。结果 在TCGA数据库中用单因素生存分析筛选出899个与生存预后相关的LncRNA,进一步用多因素Cox回归,筛选出5个与生存预后最显著相关的LncRNA,并构建肝细胞癌预后模型,其受试者工作特征曲线的曲线下面积表明该模型对肝细胞癌的三年和五年生存率的评估有很好地准确性,可能是肝细胞癌发生发展中的关键基因,为后期临床及动物实验提供研究方向和依据。结论 研究确定了肝细胞癌中与生存预后显著相关的5个LncRNA,包括B3GALT5-AS,KC877982.1,MIR7-3JG,PGM5P3-AS1和TBX5-AS1(P<0.01)。其表达特征与患者的存活风险具有较高的关联性,联合检测这5个LncRNA能较准确地预测肝细胞癌患者的三年和五年生存率。
Abstract:
Objective The cancer genome atlas(TCGA)database was used to construct a long-chain non-coding RNA(LncRNA)screening modelrelated to survival and prognosis of patients with hepatocellular carcinoma(HCC)by bioinformatics method.The LncRNA related to diagnosis and prognosis of HCC was established,which provided a new research idea for the occurrence,development and prognosis of HCC and was expected to become a new therapeutic target.Methods RNA expression profiles and clinical data of 424 patients with hepatocellular carcinoma(HCC)were downloaded from the cancer gene map(TCGA)database,including 374 tumors and 50 normal controls.LncRNA differentially expressed in normal tissues and hepatocellular carcinoma tissues wasobtained by edgeR package of R language,and LncRNA related to prognosis was screened by single factor Cox regression analysis.LncRNA model related to prognosis of hepatocellular carcinoma was established by lasso regression and multivariate regression analysis.The working characteristic curve of subjects was drawnto verify the reliability of the model.Results 899 LncRNAs related to survival and prognosis were screened out by single factor survivalanalysis in TCGA database.Five LncRNAs most significantly related to survivaland prognosis were screened by multi-factor Cox regression.A prognostic modelof hepatocellular carcinoma was constructed.The area under the curve of the working characteristic curve of the subjects showed that the model was very accurate in evaluating the three-year and five-year survival rates of hepatocellularcarcinoma.Sex may be a key gene in the occurrence and development of hepatocellular carcinoma,providing research direction and basis for later clinical and animal experiments.Conclusion Five LncRNAs were identifiedto be significantly associated with survival and prognosis in HCC,including B3GALT5-AS,KC877982.1,MIR7-3JG,PGM5P3-AS1 and TBX5-AS1(P<0.01).Theexpression characteristics of LncRNA had a high correlation with the survival risk of patients.The combined detection of these five LncRNA can accurately predict the 3-year and 5-year survival rates of patients with hepatocellular carcinoma.

参考文献/References:

[1] 颜丽,魏莲花,齐发梅,等.血清TSGF,AFP,CEA和FER联合检测在肝脏恶性肿瘤诊断中的应用价值[J].现代检验医学杂志,2018,33(5):24-26,141. YAN Li,WEI Lianhua,QI Famei,et al.Significance of combined detection of TSGF,AFP,CEA and FER in the diagnosis of hepatic malignancy[J].Journal of Modern Laboratory Medicine,2018,33(5):24-26,141. [2] LI Haiyan,AN Jiahui,WU Mengying,et al.LncRNA HOTAIR promotes human liver cancer stemcell malignant growth through downregulation of SETD2[J].Oncotarget,2015,6(29):27847-27864. [3] ZHENG Zhikun,PANG Cui,YANG Yang,et al.Serum long noncoding RNA urothelial carcinoma-associated 1:A novel biomarker for diagnosis and prognosis ofhepatocellular carcinoma[J].J Int Med Res,2018,46(1):348-356. [4] ZHANG Junyong,ZHANG Di,ZHAO Qi,et al.A distinctively expressed long noncoding RNA,RP11-466I1.1,may serve as a prognostic biomarker in hepatocellular carcinoma[J].Cancer Med,2018,7(7):2960-2968. [5] WANG Liang,WEI Zhewei,WU Kaiming,et al.Long noncoding RNA B3GALT5-AS1 suppresses colon cancer liver metastasis via repressing microRNA-203[J].Aging(Albany NY),2018,10(12):3662-3682. [6] ZHANG Yaqing,WANG Yong,LIU Huaidong,et al.Six genes as potential diagnosis and prognosis biomarkers for hepatocellular carcinoma through data mining[J].J Cell Physiol,2018:1-6.https://doi.org/10.1002/JCP.27664. [7] QIAO Fang,LI Na,LI Wei.Integrative bioinformatics analysis reveals potential long non-coding RNA biomarkers and analysis of function in non-smokingfemales with lung cancer[J].Med Sci Monit,2018,24:5771-5778. [8] LANGE N,DUFOUR JF.Changing epidemiology of HCC:how to screen and identify patients at Risk[J].Dig Dis Sci,2019,64(4):903-909. [9] YANG Minghui, YEN Chiahung, CHEN Yenfu,et al.Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma[J].Sci Rep,2019,9(1):2552. [10] SUN Xiangjun,WANG Mingchun,ZHANG Fenghua,et al.Inhibition ofNET-1 suppresses proliferation and promotes apoptosis of hepatocellular carcinoma cells by activating the PI3K/AKT signaling pathway[J].EXP Ther Med.2019,17(3):2334-2340. [11] QIAN Fuliang,HU Qingqing,TIAN Yali,et al.ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis[J].Int J Biol Sci,2019,15(2):369-385.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(04):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(04):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[7]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[8]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[9]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(04):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
[10]吴翠婷,周雪辉,张婉馨.基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1 抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J].现代检验医学杂志,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]
　WU Cuiting,ZHOU Xuehui,ZHANG Wanxin.Differential Expression of Glycolysis-related Genes in Patients with Advanced Hepatocellular Carcinoma Treated with PD-1 Inhibitors Screened Based on Biological Information Analysis, and Survival Benefit Model Constructed and Verified[J].Journal of Modern Laboratory Medicine,2023,38(04):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]

备注/Memo

备注/Memo:
基金项目:韶关市卫生计生科研项目(Y19046)。 作者简介:吴良银(1980-),男,硕士研究生,主管检验师,从事临床医学检验与分子诊断研究,E-mail:53537972@qq.com。 通讯作者:刘 俊,硕士研究生,从事临床医学检验与分子诊断研究,E-mail:liuyu8566@126.com。收稿日期:2019-03-28 修回日期:2019-05-22
更新日期/Last Update: 2019-07-30